Invesco Ltd. Sells 22,037 Shares of Aurinia Pharmaceuticals Inc $AUPH

Invesco Ltd. lowered its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 15.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 122,075 shares of the biotechnology company's stock after selling 22,037 shares during the period. Invesco Ltd. owned 0.09% of Aurinia Pharmaceuticals worth $981,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new position in Aurinia Pharmaceuticals in the fourth quarter worth approximately $27,000. Tower Research Capital LLC TRC boosted its holdings in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in Aurinia Pharmaceuticals in the fourth quarter worth approximately $31,000. GAMMA Investing LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 1,744 shares in the last quarter. Finally, USA Financial Formulas bought a new position in shares of Aurinia Pharmaceuticals in the first quarter valued at approximately $50,000. Institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Stock Performance

AUPH stock traded down $0.13 during midday trading on Friday, hitting $12.40. The company's stock had a trading volume of 1,825,129 shares, compared to its average volume of 1,785,721. The stock's 50-day moving average price is $10.28 and its 200 day moving average price is $8.82. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a 1 year low of $6.42 and a 1 year high of $12.82. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of 28.84 and a beta of 1.26.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The business had revenue of $70.01 million during the quarter, compared to analysts' expectations of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang purchased 200,000 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The shares were bought at an average cost of $11.68 per share, for a total transaction of $2,336,000.00. Following the purchase, the director owned 11,329,500 shares of the company's stock, valued at $132,328,560. This represents a 1.80% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have purchased 1,300,000 shares of company stock worth $13,590,000. Corporate insiders own 12.20% of the company's stock.

Wall Street Analyst Weigh In

AUPH has been the topic of a number of recent research reports. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Royal Bank Of Canada raised their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a report on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $12.00.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.